Product Description: Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
Applications: Cancer-Kinase/protease
Formula: C28H22F3N7O
Citations: ACS Chem Biol. 2016 Apr 15;11(4):992-1000./Biomaterials. 16 September 2022./Biomed Chromatogr. 2019 Dec;33(12):e4674./Biomolecules. 2022 Jun 11;12(6):819./bioRxiv. 2024 Dec 22:2024.12.21.629902./bioRxiv. 2024 May 8:2024.05.07.592424./Br J Cancer. 2021 Nov 24./Breast Cancer Res. 2023 May 5;25(1):51./Cancer Biol Ther. 2019;20(6):877-885./Cancer Lett. 2024 Aug 1:217150./Cancer Med. 2016 Nov;5(11):3223-3234./Cancer Res. 2024 Oct 22./Cell Death Dis. 2021 Sep 25;12(10):875./Cell Mol Immunol. 2024 Aug;21(8):856-872./Cell Syst. 2018 Apr 25;6(4):424-443.e7./Diseases. 2023 Oct 23;11(4):147./Eur J Pharmacol. 2021 Feb 10;173944./Glia. 2022 Feb 13./Harvard Medical School LINCS LIBRARY/Int J Mass Spectrom. 442 (2019) 44-50./J Pharm Sci. 2017 Sep;106(9):2632-2641./Leuk Lymphoma. 2015;56(8):2416-23. /Oncotarget. 2018 Apr 24;9(31):22158-22183. /Patent. US20190084960A1/Patent. US20210299273A1./Research Square Preprint. 2024 Nov 06./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Stem Cell Reports. 2019 May 14;12(5):996-1006. /Target Oncol. 2020 Oct;15(5):659-671./Technical University of Munich. 24.01.2018./Toxicol Lett. 2022 Jun 6;S0378-4274(22)00117-5./Toxicology. 2024 May 15:505:153830./Xenobiotica. 2018 Oct;48(10):1059-1071. /bioRxiv. January 25, 2022./Cell Rep Methods. 2023 Oct 23;3(10):100599./Drug Metab Pharmacokinet. 2020 Feb;35(1):102-110.
References: [1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20./[2]Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9(9):e107613./[3]Dervis Hakim G, et al. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol. 2015 Nov 28;21(44):12576-85./[4]Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. J Pharm Sci. 2017 Sep;106(9):2632-2641./[5]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.
CAS Number: 641571-10-0
Molecular Weight: 529.52
Compound Purity: 99.94
Research Area: Cancer
Solubility: DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Autophagy;Bcr-Abl
Deutsch
English
